Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sepiapterin
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : PTC Therapeutics
Deal Size : $366.0 million
Deal Type : Acquisition
PTC Therapeutics to Acquire Censa Pharmaceuticals
Details : Censa Pharmaceuticals acquisition diversifies and strengthens PTC 's portfolio of rare disorders by adding the lead orphan metabolic disease drug, CNSA-001.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $10.0 million
June 05, 2020
Lead Product(s) : Sepiapterin
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : PTC Therapeutics
Deal Size : $366.0 million
Deal Type : Acquisition